User:Josef D. Jarhult

From OpenWetWare
Revision as of 06:17, 14 April 2016 by Josef D. Jarhult (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

Contact Info

Josef D. Jarhult

Josef D. Järhult, MD, PhD, Consultant Infectious Diseases

Physician and researcher, Section for Infectious Diseases, Department of Medical Sciences, Uppsala University

Uppsala Academic Hospital, SE-75185, Uppsala, Sweden

josef.jarhult@medsci.uu.se

Education

  • 2003, MD, Uppsala University
  • 2011, PhD in Infectious Diseases, Uppsala University, "Tamiflu® - Use It and Lose It?"
  • 2012, Specialized physician in Infectious Diseases, Uppsala Academic Hospital

Research interests

  1. Antimicrobial resistance
  2. Pharmaceuticals in the environment
  3. One health, i.e. the multidisciplinary approach to the human-animal-environment interface

Grants

Main applicant and project coordinator for the Swedish Research Council FORMAS grant “Neuraminidase inhibitors in the environment and resistance development to influenza A virus: implications for public health”, awarded 8,5 million SEK 2013

Co-applicant for the Swedish Research Council FORMAS grant “Readdressing Campylobacter jejuni epidemiology and evolution”, awarded 5,3 million SEK 2014

Co-applicant for the Swedish Research Council grant “Evolution of influenza A virus and antiviral resistance”, awarded 5,8 million SEK 2013

Co-applicant for the SciLifeLab grant “Discovering mechanisms of resistance to antibiotics that target the peptidyl transferase centre of the ribosome”, awarded 1,4 million SEK 2012

Awarded grant as 30-50% researcher for 3-5 years from Uppsala University and Uppsala University Hospital (corresponding to approximately 2 million SEK) 2014

Awarded grant as “Clinical Research Fellow”, MIMS, Umeå University 2012 (1 million SEK, half-time employment for two years)

Scientific Merits

Section Editor, Infection Ecology & Epidemiology

One of Sweden’s two nominated members of the Management Committee of the pan-European COST Action TD1404 “Network for Evaluation of One Health (NEOH)”

Member of the “expert group” in the evaluation of the National Vaccination Program for Influenza by the Swedish Board for Health and Welfare

Invited Speaker, “Influenza Day”, Swedish Public Health Agency 2015

Invited Speaker, International Caparica Conference in Antibiotic Resistance 2015

Invited Speaker, World Health Day 2014 “Ensuring Health & Sustainability in Europe: Doctors and Veterinarians Emphasize: Prevention is Better Than Cure”, arranged by FVE, CPME and the European Commission

Keynote Speaker, One Health Nordic Conference 2014

“Invited Young Scientist”, Invited speaker at NSCMID 2012

Teaching Experience

Since 2008, I have regularly been teaching at, and intermittently joint responsible for, the course in Infectious Diseases at the Medical School, Uppsala University. I have completed approximately 80 hours of lecturing and 300 hours of group teaching, mainly at the Medical School but also on other undergraduate and postgraduate educations in the medical field. During 2013, I completed a 5 week course in University Education at Uppsala University.

Supervision

I have the following experience as main supervisor:

1 PhD student (Anna Gillman) graduated April 2016 (Tamiflu® in the Water: Resistance Dynamics of Influenza A Virus in Mallards Exposed to Oseltamivir, External Examiner Dr. Elena Govorkova, S:t Jude’s Research Hospital, Memphis, TN)

Currently, I supervise 1 post-doc (Michelle Wille), and 3 Ph.D. students (Clara Atterby, Marie Nykvist, and Erik Skog).

Master thesis supervision: 8 medical students and 1 veterinary student (completed), 1 medical student (ongoing).

Bachelor thesis supervision: 1 student (ongoing)

Publications

Journal Articles:

1. Resting microglial cells in vitro: analysis of morphology and adhesion molecule expression in organotypic hippocampal slice cultures. Hailer NP, Jarhult JD, Nitsch R. Glia. 1996 Dec;18(4):319-31. PMID: 8972800

2. Detection of the antiviral drug oseltamivir in aquatic environments. Söderström H, Järhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. PLoS One. 2009 Jun 26;4(6):e6064. doi: 10.1371/journal.pone.0006064. PMID: 19557131

3. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. Järhult JD, Muradrasoli S, Wahlgren J, Söderström H, Orozovic G, Gunnarsson G, Bröjer C, Latorre-Margalef N, Fick J, Grabic R, Lennerstrand J, Waldenström J, Lundkvist A, Olsen B. PLoS One. 2011;6(9):e24742. doi: 10.1371/journal.pone.0024742. Epub 2011 Sep 12. PMID: 21931841

4. Oseltamivir (Tamiflu(®)) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a review. Järhult JD. Infect Ecol Epidemiol. 2012;2. doi: 10.3402/iee.v2i0.18385. Epub 2012 Jun 21. PMID: 22957124

5. Pathobiology and virus shedding of low-pathogenic avian influenza virus (A/H1N1) infection in mallards exposed to oseltamivir. Bröjer C, Järhult JD, Muradrasoli S, Söderström H, Olsen B, Gavier-Widén D. J Wildl Dis. 2013 Jan;49(1):103-13. doi: 10.7589/2011-11-335. PMID: 23307376

6. Compliance to oseltamivir among two populations in Oxfordshire, United Kingdom affected by influenza A(H1N1)pdm09, November 2009--a waste water epidemiology study. Singer AC, Järhult JD, Grabic R, Khan GA, Fedorova G, Fick J, Lindberg RH, Bowes MJ, Olsen B, Söderström H. PLoS One. 2013 Apr 15;8(4):e60221. doi: 10.1371/journal.pone.0060221. Print 2013. PMID: 23613721

7. Zero prevalence of extended spectrum beta-lactamase-producing bacteria in 300 breeding Collared Flycatchers in Sweden. Järhult JD, Stedt J, Gustafsson L. Infect Ecol Epidemiol. 2013 Jul 25;3. doi: 10.3402/iee.v3i0.20909. Print 2013. PMID: 23898397

8. Resistance Mutation R292K Is Induced in Influenza A(H6N2) Virus by Exposure of Infected Mallards to Low Levels of Oseltamivir. Gillman A, Muradrasoli S, Söderström H, Nordh J, Bröjer C, Lindberg RH, Latorre-Margalef N, Waldenström J, Olsen B, Järhult JD. PLoS One. 2013 Aug 12;8(8):e71230. doi: 10.1371/journal.pone.0071230. PMID: 23951116

9. Why Is It So Hard to Understand One Health? Artursson K, Järhult JD, Olsen B, Berg, C. Svensk Veterinärtidning [Swedish Veterinary Journal, article in Swedish]. 2014 Feb;2:35-39

10. Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in sweden. Orozovic G, Orozovic K, Järhult JD, Olsen B. PLoS One. 2014 Feb 18;9(2):e89306. doi: 10.1371/journal.pone.0089306. eCollection 2014.

11. Antibiotic resistance in wild birds. Bonnedahl J, Järhult JD. Ups J Med Sci. 2014 May;119(2):113-6. doi: 10.3109/03009734.2014.905663. Epub 2014 Apr 4.

12. Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers. Singer AC, Järhult JD, Grabic R, Khan GA, Lindberg RH, Fedorova G, Fick J, Bowes MJ, Olsen B, Söderström H. PLoS One. 2014 Sep 25;9(9):e108621. doi: 10.1371/journal.pone.0108621. eCollection 2014.

13. Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards. Gillman A, Muradrasoli S, Söderström H, Holmberg F, Latorre-Margalef N, Tolf C, Waldenström J, Gunnarsson G, Olsen B, Järhult JD. Appl Environ Microbiol. 2015 Apr;81(7):2378-83. doi: 10.1128/AEM.04034-14. Epub 2015 Jan 23. PMID: 25616792

14. One Health: a doctor's perspective. Järhult JD. Vet Rec. 2015 Apr 4;176(14):351-3. doi: 10.1136/vr.h839. PMID: 25837947

15. Online solid phase extraction liquid chromatography using bonded zwitterionic stationary phases and tandem mass spectrometry for rapid environmental trace analysis of highly polar hydrophilic compounds - Application for the antiviral drug Zanamivir. Lindberg RH, Fedorova G, Blum KM, Pulit-Prociak J, Gillman A, Järhult JD, Appelblad P, Söderström H. Talanta. 2015 Aug 15;141:164-9. doi: 10.1016/j.talanta.2015.03.066. Epub 2015 Apr 8. PMID: 25966397

16. Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. Gillman A, Nykvist M, Muradrasoli S, Söderström H, Wille M, Daggfeldt A, Bröjer C, Waldenström J, Olsen B, Järhult JD. Antimicrob Agents Chemother. 2015 Sep;59(9):5196-202. doi: 10.1128/AAC.00886-15. Epub 2015 Jun 15. PMID: 26077257

17. Tamiflu - what we know about its ups and downs. Järhult JD. British Journal of Virology, 2015, 2(3): 49-52. http://smithandfranklin.com/current-issues/Tamiflu-What-we-Know-About-its-Ups-and-Downs/6/6/105/html#QczLily4VWuIzpvF.99

18. Mallard or chicken? Comparing the isolation of avian influenza A viruses in embryonated Mallard and chicken eggs. Järhult JD, Wahlgren J, Hasan B, Salaneck E, Lundkvist Å. Infect Ecol Epidemiol. 2015 Sep 8;5:28458. doi: 10.3402/iee.v5.28458. eCollection 2015. PMID: 26356095

19. Oseltamivir Resistance in Influenza A(H6N2) Caused by an R292K Substitution in Neuraminidase Is Not Maintained in Mallards without Drug Pressure. Gillman A, Muradrasoli S, Mårdnäs A, Söderström H, Fedorova G, Löwenthal M, Wille M, Daggfeldt A, Järhult JD. PLoS One. 2015 Sep 30;10(9):e0139415. doi: 10.1371/journal.pone.0139415. eCollection 2015. PMID: 26422258

20. Absence of vancomycin-resistant enterococci among highly ESBL-positive crows (Corvus splendens) foraging on hospital waste in Bangladesh. Hasan B, Järhult JD. Infect Ecol Epidemiol. 2015 Dec 15;5:29761. doi: 10.3402/iee.v5.29761. eCollection 2015. PMID: 26679560

21. Fate of three anti-influenza drugs during ozonation of wastewater effluents - degradation and formation of transformation products. Fedorova G, Grabic R, Nyhlen J, Järhult JD, Söderström H. Chemosphere. 2016 May;150:723-30. doi: 10.1016/j.chemosphere.2015.12.051. Epub 2015 Dec 30. PMID: 26746418

22. One Health expedition to Galapagos Islands. Artursson K, Berg C, Järhult JD, Andersson DI, Olsen B. Svensk Veterinärtidning [Swedish Veterinary Journal, article in Swedish]. 2016 Jan;1:37-41

23. A Panel of Stably Expressed Reference Genes for Real-Time qPCR Gene Expression Studies of Mallards (Anas platyrhynchos). Chapman JR, Helin AS, Wille M, Atterby C, Järhult JD, Fridlund JS, Waldenström J. PLoS One. 2016 Feb 17;11(2):e0149454. doi: 10.1371/journal.pone.0149454. eCollection 2016. PMID: 26886224

24. High Prevalence and Putative Lineage Maintenance of Avian Coronaviruses in Scandinavian Waterfowl. Wille M, Muradrasoli S, Nilsson A, Järhult JD. PLoS One. 2016 Mar 3;11(3):e0150198. doi: 10.1371/journal.pone.0150198. eCollection 2016. PMID: 26938459

25. Fecal Carriage of Extended-Spectrum β-Lactamases in Healthy Humans, Poultry, and Wild Birds in León, Nicaragua-A Shared Pool of blaCTX-M Genes and Possible Interspecies Clonal Spread of Extended-Spectrum β-Lactamases-Producing Escherichia coli. Hasan B, Laurell K, Rakib MM, Ahlstedt E, Hernandez J, Caceres M, Järhult JD. Microb Drug Resist. 2016 Mar 23. [Epub ahead of print] PMID: 27007258

Book Chapters:

Järhult, J.D. (2013). Environmental Resistance Development to Influenza Antivirals - and the Return to Humans. Virology II – Advanced Issues. ISBN: 978-1-922227-27-0. iConcept Press. Retrieved from http://www.iconceptpress.com/books/virology-ii-advanced-issues/

Olsen B, Järhult JD, Waldenström J, Berg C. (2014). One Health- a necessary approach for the future. pp. 47-52. In A Changing World: Redrawing the map. The 11th Royal Colloquium, May 2013. E. Kessler and A. Karlqvist eds.